Such negative impact extends to tumors with high PD-L1 expression and is further associated with primary resistance to combined PD-L-1/cytotoxic T-lymphocyte associated-protein 4 (CTLA-4) blockage in NSCLC [188]. Here, CTLA4 is linked to non-small cell lung carcinoma.